AUROPHARMA
Aurobindo Pharma Limited (AUROPHARMA) Stock Analysis
Aurobindo Pharma Limited is a major Indian generic pharmaceutical company with global scale in APIs and formulations. It manufactures medicines for the US, Europe, and emerging markets across oral, injectable, and biosimilar categories. The company operates large manufacturing campuses in India. It is a large-cap listed pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,666.90
-1.54% 1W | +52.40% 52W
Market Cap
95.9k CR
P/E Ratio
26
52W High
₹1740
52W Low
₹1080.1
Div. Yield
0%
Beta
0
50 DMA
₹1668.4
200 DMA
₹1446.9
Profit Margin
10.6%
Inst. Own.
29.2%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Expenses | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 |
| Operating Profit | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 |
| OPM % | 17% | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% |
| Other Income | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax % | 30% | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% |
| Net Profit | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS in Rs | 9.74 | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.95 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 34,935 |
| Expenses | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,164 | 26,783 | 27,854 |
| Operating Profit | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,081 |
| OPM % | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% | 20% | 20% |
| Other Income | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 613 | 404 | 586 |
| Interest | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 | 388 |
| Depreciation | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,778 | 1,859 |
| Profit before tax | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,112 | 5,420 |
| Tax % | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | 31% | 31% | |
| Net Profit | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,711 |
| EPS in Rs | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 60.34 | 64.09 |
| Dividend Payout % | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% | -0% | 7% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 11.0% | 6.0% | 9.0% |
| Profit CAGR | 23.0% | 1.0% | 6.0% |
Shareholding Pattern
Promoters51.82%
FIIs14.38%
DIIs26.93%
Public6.88%
Promoters51.82%
FIIs14.21%
DIIs27.60%
Public6.37%
Promoters51.82%
FIIs13.95%
DIIs27.66%
Public6.55%
Promoters51.82%
FIIs15.24%
DIIs25.82%
Public7.08%
Promoters51.88%
FIIs16.38%
DIIs25.05%
Public6.63%
Promoters51.84%
FIIs23.03%
DIIs15.09%
Public10.06%
Promoters51.84%
FIIs18.01%
DIIs23.28%
Public6.87%
Promoters51.82%
FIIs15.33%
DIIs26.23%
Public6.61%
Promoters51.82%
FIIs15.24%
DIIs25.82%
Public7.08%
Promoters51.88%
FIIs16.38%
DIIs25.05%
Public6.63%
AUROPHARMA
Holdings Analysis
Key strengths & risk signals
75
Overall
83
Fundamental
68
Technical
Risks (2)
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
RECOVERY MODE! Current price (1666.9) above 200-day but below 50-day.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1668.4) is above 200-day average (1446.9) - positive signal.
EXCELLENT YEAR! Stock gained 52.4% in the last year.
STRONG! Trading at 88.9% of 52W range - near yearly highs.
Fundamental & Technical Analysis
75Overall
83Fundamental
68Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 10.7% (GOOD, 11/15). Profit CAGR: 22.1% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.6% profit margin - acceptable profitability.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.18 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.25 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 8.31% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1668.4) is above 200-day average (1446.9) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1666.9) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 52.4% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 862,496 vs down days: 761,187. Ratio: 1.13x
RSI
3/5
NEUTRAL! RSI at 48.1 - balanced momentum.
52W Range
5/5
STRONG! Trading at 88.9% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -1.5% (1 week), 1.4% (1 month), 8.7% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
AUROPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-13 | Concall PDF | |
| Q4FY262026-05-27 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUROPHARMA | ₹1,666.90 | 26 | 10.6% | 10.7% | 22.1% | +52.4% | 75 | BREAKDOWN | +25.2% | +12.1% | +16.9% | +4.0% |
| MANKIND | ₹2,275.50 | 46 | 13.9% | 17.7% | 14.3% | -5.2% | 70 | BREAKDOWN | +29.6% | +2.5% | +12.9% | +17.1% |
| LUPIN | ₹1,961.60 | 16.2 | 18.5% | 19.1% | 131.5% | +0.7% | 66 | APPROACHING RESISTANCE | +16.1% | -3.1% | +33.3% | +11.2% |
| DRREDDY | ₹1,233.00 | 31 | 10.0% | 11.0% | -1.7% | -2.0% | 59 | HIT RESISTANCE | -68.7% | +100.8% | -5.6% | +7.4% |
| CIPLA | ₹1,325.10 | 31.8 | 12.0% | 7.2% | 11.5% | -16.2% | 59 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| LAURUSLABS | ₹2,060.10 | 101.8 | 15.0% | 3.8% | 4.0% | +124.3% | 62 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| ZYDUSLIFE | ₹1,123.00 | 25 | 15.8% | 16.5% | 37.0% | +14.2% | 76 | BREAKDOWN | -35.9% | -26.1% | +20.6% | +4.9% |
| GLENMARK | ₹2,226.70 | 35 | 10.1% | 13.5% | 66.1% | +20.9% | 70 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
AUROPHARMA News
Aurobindo Pharma Limited Receives Final Approval for Perampanel Tablets from USFDA2026-10-03Aurobindo Pharma Limited Receives Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol2026-09-15Aurobindo Pharma Limited Launches Generic Advair Diskus® in US Market2026-08-31Aurobindo Pharma Limited (auropharma) Q1fy27: Revenue Up 16.3%, Net Profit Rises 25.2%2026-08-05Aurobindo Pharma Limited (auropharma) Receives FTC Approval to Acquire Lannett Company2026-06-22Aurobindo Pharma Limited Receives Final US FDA Approval for Tofacitinib Tablets2026-06-04Aurobindo Pharma Limited (auropharma) Unveils Theranym Biologics Facility in Hyderabad2026-06-03Aurobindo Pharma Limited (auropharma) Reports Q4 FY26 Results: Revenue Up 5.6% Yoy2026-05-21
